Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
J Antimicrob Chemother ; 78(1): 117-121, 2022 12 23.
Article in English | MEDLINE | ID: mdl-36272137

ABSTRACT

OBJECTIVES: We aimed to investigate and compare the efficacy and safety of two dolutegravir-based two-drug regimens: dolutegravir + lamivudine versus dolutegravir + rilpivirine. METHODS: We analysed a cohort of people living with HIV (PLWHIV) switching to dolutegravir + lamivudine or dolutegravir + rilpivirine. We excluded from the analysis PLWHIV with no available pre-switch genotypic test or with a known resistance mutation to one of the study drugs. We evaluated incidence of virological failure (VF) and treatment discontinuation (TD), as well as changes in immunological and metabolic parameters. RESULTS: We enrolled 592 PLWHIV: 306 in the lamivudine group and 286 in the rilpivirine group. We observed nine VFs in the lamivudine group [1.4 VF per 100 patient-years of follow-up (PYFU)] and four VFs in the rilpivirine group (0.6 VF per 100 PYFU). Subsequent genotypic analysis showed no acquired resistance-associated mutations in those experiencing VF. Estimated probability of maintaining virological suppression at 144 and 240 weeks were 96.6% and 92.7%, respectively, in the lamivudine group and 98.7% and 98.7%, respectively, in the rilpivirine group (log-rank P = 0.172). The estimated probability of maintaining study regimen at Week 240 was 82.3% in the lamivudine group and 85.9% in the rilpivirine group (log-rank P = 0.018). We observed a significant improvement in CD4+ cell count at Week 240 in the lamivudine group (P = 0.012); in the rilpivirine group we registered a significant increase in CD4/CD8 ratio (P = 0.014). CONCLUSIONS: Both analysed strategies are effective and safe as switch strategies in clinical practice, with a low incidence of VF and a favourable immunological recovery, even in the long term.


Subject(s)
Anti-HIV Agents , HIV Infections , Humans , Lamivudine/adverse effects , HIV Infections/drug therapy , Anti-HIV Agents/adverse effects , Rilpivirine/adverse effects , Heterocyclic Compounds, 3-Ring/adverse effects , Pyridones/therapeutic use , Oxazines/therapeutic use
4.
Brain Res Bull ; 151: 3-11, 2019 09.
Article in English | MEDLINE | ID: mdl-30593881

ABSTRACT

Neurogenesis is a process of generating functional neurons, which occurs during embryonic and adult stages in mammals. While neurogenesis during development phase is characterized by intensive proliferation activity in all regions of the brain to form the architecture and neural function of the nervous system, adult neurogenesis occurs with less intensity in two brain regions and is involved in the maintenance of neurogenic niches, local repair, memory and cognitive functions in the hippocampus. Taking such differences into account, the understanding of molecular mechanisms involved in cell differentiation in developmental stages and maintenance of the nervous system is an important research target. Although embryonic and adult neurogenesis presents several differences, signaling through purinergic receptors participates in this process throughout life. For instance, while embryonic neurogenesis involves P2X7 receptor down-regulation and calcium waves triggered by P2Y1 receptor stimulation, adult neurogenesis may be enhanced by increased activity of A2A and P2Y1 receptors and impaired by A1, P2Y13 and P2X7 receptor stimulation.


Subject(s)
Neurogenesis/physiology , Receptors, Purinergic/metabolism , Receptors, Purinergic/physiology , Adenosine Triphosphate , Animals , Brain/cytology , Calcium/metabolism , Calcium Signaling , Cell Differentiation , Cell Proliferation , Hippocampus/cytology , Humans , Nervous System , Purines/metabolism , Receptors, Purinergic P2X7/metabolism , Receptors, Purinergic P2Y1/metabolism , Signal Transduction/physiology
5.
HIV Med ; 20(2): 164-168, 2019 02.
Article in English | MEDLINE | ID: mdl-30457197

ABSTRACT

OBJECTIVES: The aim of the study was to compare the efficacy and tolerability of switching antiretroviral therapy to dolutegravir + emtricitabine/tenofovir disoproxil fumarate (TDF) with those of switching to elvitegravir/cobicistat/emtricitabine/TDF in clinical practice. METHODS: In a multicentre real-life observational study, we analysed data for HIV-infected patients on antiretroviral treatment with viral load < 50 HIV-1 RNA copies/mL switching to dolutegravir + emtricitabine/TDF (dolutegravir group) or elvitegravir/cobicistat/emtricitabine/TDF (elvitegravir group). Follow-up was censored at 48 weeks. RESULTS: The 48-week estimated proportion maintaining virological efficacy was 96.1% with dolutegravir (n = 123) and 95.4% with elvitegravir (n = 186; P = 0.941). Patients in the dolutegravir group showed more treatment discontinuations, but these were mainly as a result of simplification. The elvitegravir group showed more discontinuations because of renal adverse events (2.7% versus 0% with dolutegravir). Interestingly, no difference was observed between the two regimens in central nervous system toxicity-related discontinuations. Switching to dolutegravir was associated with a better blood lipid profile. CONCLUSIONS: Switching to dolutegravir + emtricitabine/TDF was associated with similar efficacy and tolerability to switching to elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed patients in clinical practice, although reasons for discontinuation showed differences between regimens. These results should be interpreted with caution, as this is a nonrandomized comparison.


Subject(s)
Cobicistat/therapeutic use , Emtricitabine/therapeutic use , HIV Infections/drug therapy , Heterocyclic Compounds, 3-Ring/therapeutic use , Quinolones/therapeutic use , Tenofovir/therapeutic use , Adult , Cobicistat/adverse effects , Drug Therapy, Combination/adverse effects , Emtricitabine/adverse effects , Female , HIV Infections/virology , HIV-1/genetics , Heterocyclic Compounds, 3-Ring/adverse effects , Humans , Male , Middle Aged , Oxazines , Piperazines , Pyridones , Quinolones/adverse effects , RNA, Viral/genetics , Retrospective Studies , Tenofovir/adverse effects , Viral Load
6.
BMC Infect Dis ; 17(1): 396, 2017 06 05.
Article in English | MEDLINE | ID: mdl-28583112

ABSTRACT

BACKGROUND: Tenofovir (TDF) is one of the most widely used antiretroviral drug. Despite the high degree of tolerability a small percentage of patients experienced alteration in tubular function during TDF use. Intracellular TDF disposition is regulated by ATP-binding cassette (ABC) drug efflux transporters and, a reduced transport activity may be implicated in accumulation of TDF into the cells. The aim of our study was to assess the major determinants of TDF associated tubular dysfunction (KTD) in a real-life setting including the usefulness of single-nucleotide polymorphisms (SNPs) mapping into ABCC2, ABCC4 and ABCC10 genes. METHODS: We retrospectively analyzed all HIV positive patients who were followed at the Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan from April 2013 to June 2016. All patients treated with TDF who underwent a genotypization for the functional variants mapping in ABCC2 rs717620 (-24 C > T), ABCC4 rs1751034 (3463 A > G) and ABCC10 rs2125739 (T > C) were evaluated. KTD was defined as the presence of urine phosphate wasting and/or proteinuria at 24 h urine analysis. RESULTS: One hundred fifty-eight patients were genotyped, of which 42 (26.6%) experienced signs of KTD. No statistical significant differences were observed among patients with or without KTD regarding age, gender, ethnicity and comorbidities (hypertension and diabetes). The percentage of patients with KTD was higher among those with "GG" genotype at rs1751034 of ABCC4 compared to patients without KTD [6 (14.3%) vs 4 (3.5%), p = 0.01]. No statistical significant differences were observed regarding the distribution of ABCC2 and ABCC10 SNPs. Carriers of "G" allele in homozygous status at rs1751034 of ABCC4 showed a significant association with KTD (Odds Ratio 4.67, 95% CI 1.25-17.46, p = 0.02) in bivariate analysis, but this association was lost in multivariable analysis. A significant association between bone diseases and KTD was observed (Odds Ratio 3.178, 95%CI 1.529-6.603, p = 0.002). CONCLUSIONS: According to our results ABCC4 rs1751034 could be a genetic determinant of KTD; however validation studies are needed for therapy personalization. Noteworthy, a strong association between bone disease and KTD was also observed.


Subject(s)
Anti-HIV Agents/adverse effects , Kidney Diseases/chemically induced , Kidney Diseases/genetics , Polymorphism, Single Nucleotide , Tenofovir/adverse effects , Adult , Alleles , Cohort Studies , Female , HIV Infections/drug therapy , Humans , Kidney Diseases/physiopathology , Male , Middle Aged , Multidrug Resistance-Associated Protein 2 , Multidrug Resistance-Associated Proteins/genetics , Proteinuria/chemically induced
8.
Pediatr Infect Dis J ; 15(12): 1097-101, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8970219

ABSTRACT

BACKGROUND: Recurrent bacterial sepsis is common in pediatric HIV infection and immunization against Haemophilus influenzae type b (Hib) is recommended. Long term persistence of anti-Hib antibody and the need for, or timing of, a booster dose has not been adequately studied. METHODS: Immunogenicity during a 12-month period following immunization with Hib-tetanus conjugate vaccine (ACT-HIB; Merieux) was evaluated in 48 vertically HIV-infected children and 36 uninfected children, born to HIV-positive mothers. A titer of anti-Hib polysaccharide antibody of > or = 0.15 microgram/ml was considered to indicate short term and > or = 1 microgram/ml long term protection. RESULTS: At 1 month postvaccination 36 (100%) uninfected and 42 (88%) HIV-infected children achieved titers of > or = 1 microgram/ml. However, by 1 year titers had dropped below this value in 18 (43%) infected compared with only 4 (11%) uninfected children (chi square, 9.7; P = 0.002). Although the rate of fall of antibody titer was greater in uninfected than in infected children, this was no longer the case after adjustment for the 1-month postimmunization titer. The rate of antibody titer decline was not significantly related to HIV disease status or to either the age-related CD4 count at the time of immunization or the change in age-adjusted CD4 count during the 12 months after immunization. CONCLUSIONS: Not only was the initial antibody response to Hib conjugate vaccine decreased in children with HIV infection and AIDS but also 1 year later only 57% of the initial responders had persisting titers above the level associated with long term protection. The need for reimmunization of children with HIV infection against Hib requires further evaluation.


Subject(s)
AIDS-Related Opportunistic Infections/immunology , Antibodies, Bacterial/analysis , Bacteremia , Haemophilus Infections , Haemophilus Vaccines/administration & dosage , Haemophilus influenzae/immunology , Polysaccharides, Bacterial/administration & dosage , AIDS-Related Opportunistic Infections/diagnosis , Bacteremia/immunology , Bacteremia/prevention & control , Bacterial Capsules , Female , Follow-Up Studies , Haemophilus Infections/immunology , Haemophilus Infections/prevention & control , Humans , Immunization, Secondary/trends , Infant , Infectious Disease Transmission, Vertical , Male , Reference Values
10.
Pediatr Infect Dis J ; 14(2): 129-35, 1995 Feb.
Article in English | MEDLINE | ID: mdl-7746695

ABSTRACT

Antibody responses to Haemophilus influenzae type b (Hib) conjugate (ActHIB; Pasteur Merieux) and pneumococcal (Pneumovax II; Morson) vaccines were measured in 56 infected children (VI) and 44 uninfected children (U) older than 18 months of age, born to human immunodeficiency virus-positive mothers. Preimmunization, 21% U and 20% VI had protective concentrations of anti-Hib polysaccharide antibodies. Postimmunization, 100% U and 86% VI achieved protective titers (P = 0.008). The geometric mean increase in anti-Hib polysaccharide antibody was 7.6 (95% confidence interval, 3.5 to 16.3; P = 0.0001) times higher in U than in VI children after adjusting for age and ethnicity. Sixty-one percent U compared to 54% VI showed a 2-fold increase in antibody levels to at least one of the four pneumococcal vaccine serotypes (3, 6, 19, 23) measured (P = 0.4). For both vaccines there was a significant trend toward poorer responses in children with acquired immunodeficiency syndrome but no correlation with age adjusted CD4 counts. These data suggest that human immunodeficiency virus-infected children should be immunized with these polysaccharide vaccines early in the course of their disease.


Subject(s)
Antibodies, Bacterial/biosynthesis , Bacterial Vaccines/immunology , HIV Infections/congenital , HIV Infections/immunology , Haemophilus Vaccines/immunology , Haemophilus influenzae/immunology , Streptococcus pneumoniae/immunology , Tetanus Toxoid/immunology , Vaccination , Bacterial Vaccines/administration & dosage , Confidence Intervals , HIV Infections/transmission , Haemophilus Infections/prevention & control , Haemophilus Vaccines/administration & dosage , Humans , Infant , Infant, Newborn , Infectious Disease Transmission, Vertical , Pneumococcal Infections/prevention & control , Pneumococcal Vaccines , Tetanus Toxoid/administration & dosage
11.
Acta Paediatr Suppl ; 400: 70-2, 1994 Aug.
Article in English | MEDLINE | ID: mdl-7833566

ABSTRACT

Children with HIV infection have an unusual susceptibility to bacterial infection, related to several immune abnormalities. Selection of initial antibiotic therapy must be individualized in these children. Patients with community-acquired disease are most likely to have infection by polysaccharide-encapsulated bacterial organism, most commonly Streptococcus pneumoniae and less frequently by Haemophilus influenzae type b. If it is possible to treat the patients at home, the use of amoxicillin-clavulanic acid might be appropriate. Other authors propose management with parenteral ceftriaxone because of the better compliance and the malabsorption. In hospitalized patients, concern for Gram-negative enteric pathogens other than polysaccharide-encapsulated organisms requires initial therapy with a third-generation cephalosporine in combination with an aminoglycoside. Trimethoprim-sulfamethizole is the most common drug used in HIV-infected children because it is recommended for the initial therapy and for prophylaxis of pneumocystis carinii pneumonia, which occurs in as many as 42% of these children.


Subject(s)
AIDS-Related Opportunistic Infections/prevention & control , HIV Infections/complications , Sulfamethizole/therapeutic use , Trimethoprim/therapeutic use , AIDS-Related Opportunistic Infections/complications , Child , Clinical Trials as Topic , Drug Therapy, Combination , Humans
12.
Article in English | MEDLINE | ID: mdl-8073836

ABSTRACT

Recent research has demonstrated the activity of calcipotriol, effective as a potent inhibitor of cellular proliferation and known to increase differentiation in a number of cell lines in the topical treatment of psoriasis. Vit D3 receptors are expressed in keratinocytes and vascular endothelial cells. We studied the alterations in basal keratinocytes (stem cells or anchoring cells) and endothelial cell modification in 6 patients with psoriasis treated with calcipotriol ointment twice a day for 4 weeks. The samples were embedded in Epon resin for thin section and ultrathin section examination by electron microscopy. A normal pattern of distribution of the two different types of basal keratinocytes was observed before treatment. After treatment, only anchoring cells were detected. The alterations of endothelial cells in capillary loop disappeared after treatment, presenting normal aspects. Our morphological findings suggest that calcipotriol is therapeutically effective, due principally to an inhibition of cellular proliferation.


Subject(s)
Calcitriol/analogs & derivatives , Dermatologic Agents/therapeutic use , Endothelium, Vascular/ultrastructure , Keratinocytes/pathology , Psoriasis/drug therapy , Skin/blood supply , Calcitriol/therapeutic use , Capillaries/ultrastructure , Humans , Psoriasis/pathology
13.
Minerva Gastroenterol Dietol ; 39(1): 17-22, 1993 Mar.
Article in Italian | MEDLINE | ID: mdl-8357881

ABSTRACT

The paper examines a series of 172 patients undergoing endoscopic intubation with plastic stent due to unoperable esophago-gastric tumoral stenoses during the period 1980-1991. An analysis of the data enabled the following conclusions to be drawn: (1) The majority of perforations occur during the treatment of distal stenoses (15%), anastomotic stenosis (20%) and extrinsic compression stenoses (23% vs 7% in the case of stenosing primary esophageal neoplasia). (2) Severe respiratory problems may occur during treatment of cervical stenoses. (3) Malfunctioning of prostheses is more frequent in the treatment of cardias stenosis (10%). Having a few technical comments on the subject of passing the guide thread through the most twisting and narrow stenoses, the authors express the wish that expandable metal prostheses will be more widely used in order to render the method less traumatic, increase the percentage of success (extending the indications regarding the site and type of stenosis) and reduce severe complications.


Subject(s)
Esophageal Neoplasms/complications , Esophageal Stenosis/therapy , Esophagoscopy , Gastroscopy , Intubation/methods , Stomach Diseases/therapy , Stomach Neoplasms/complications , Adult , Constriction, Pathologic/etiology , Constriction, Pathologic/therapy , Esophageal Stenosis/etiology , Esophagoscopy/adverse effects , Gastroscopy/adverse effects , Humans , Intubation/adverse effects , Prostheses and Implants/adverse effects , Risk Factors , Stomach Diseases/etiology
14.
Arch Dis Child ; 66(10): 1235-8, 1991 Oct.
Article in English | MEDLINE | ID: mdl-1953010

ABSTRACT

In a multicentre study on perinatal HIV-I infection including 1493 children born from 1471 pregnancies to 1415 infected mothers, 22 twin pairs and 56 sibships (115 children) were recorded. The frequency of twin pregnancies was 1.5 (22/1471) and 3.9% (56/1415) seropositive women had more than one at risk pregnancy. In 18 twin pairs with a known infection status nine of the 36 children (25%) were infected. Discordance in infection status was present in only one (5.5%) dizygous pair. A high relative risk of infection (23.1) in a twin was observed when the other was infected. Infection was unrelated to gestational age, mode of delivery, or birth weight. Infection status was defined in 41 sibships (84 children including one first born twin pair and one third born child). When the first born was infected, 11/26 (42.3%) second born children were also infected, whereas this happened in only 2/16 (12.5%) second or third born children when the first born was uninfected. Two out of nine first born (22.2%) and 5/21 (23.8%) second born children prospectively followed up from birth acquired the infection. Results of this study demonstrate that neither twin nor second pregnancies are at increased risk of mother to child HIV-I transmission. Overall data suggest that non-casual factors in mother and/or child influence perinatal infection.


Subject(s)
Diseases in Twins/etiology , HIV Infections/transmission , HIV Seropositivity , HIV-1 , Pregnancy Complications, Infectious , Female , Humans , Infant , Infant, Newborn , Male , Pregnancy , Prospective Studies , Risk Factors
18.
Eur J Pharmacol ; 48(2): 179-93, 1978 Mar 15.
Article in English | MEDLINE | ID: mdl-639848

ABSTRACT

The effect of noradrenaline (NA) on acetylcholine (ACh) release from guinea-pig brain was investigated in superfused cerebral cortex slices and in unrestrained unanaesthetized animals provided with epidural cups. The amine reduced the ACh release from electrically stimulated tissue and its effect was antagonized by phentolamine and phenoxybenzamine, but not by propranolol and spiroperidol. The injection of NA (150 microgram) into the cerebral ventricles caused sedation, E.Co.G. synchronization and reduced ACh outflow from the parietal cortex. This inhibition was counteracted by alpha-blocking agents. A lower dose of NA (50 microgram) did not change the behaviour, but produced a late increase in ACh outflow, prevented by spiroperidol. These results fit well with the hypothesis that NA restrains, via alpha-receptors, the ACh secretion from the nerve endings and indirectly support the view that the amine reduces the firing rate of the corticopetal cholinergic neurones. The late increase in ACh outflow, observed in vivo, may be referred to secondary activation of the dopaminergic neurones, known to enhance the cortical ACh release in this animal species.


Subject(s)
Acetylcholine/metabolism , Brain/metabolism , Norepinephrine/pharmacology , Animals , Brain/drug effects , Catecholamines/antagonists & inhibitors , Electric Stimulation , Electroencephalography , Female , Guinea Pigs , In Vitro Techniques , Male , Norepinephrine/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL
...